New York Life Investment Management LLC Acquires 1,646 Shares of Qiagen (NYSE:QGEN)

New York Life Investment Management LLC increased its holdings in shares of Qiagen (NYSE:QGEN) by 6.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,860 shares of the company’s stock after purchasing an additional 1,646 shares during the period. New York Life Investment Management LLC’s holdings in Qiagen were worth $1,123,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. Sivik Global Healthcare LLC bought a new position in Qiagen in the fourth quarter valued at approximately $2,389,000. Sector Gamma AS lifted its position in Qiagen by 89.2% in the 4th quarter. Sector Gamma AS now owns 190,539 shares of the company’s stock valued at $8,275,000 after acquiring an additional 89,826 shares in the last quarter. Jennison Associates LLC boosted its stake in Qiagen by 15.6% in the 4th quarter. Jennison Associates LLC now owns 1,308,304 shares of the company’s stock worth $56,820,000 after purchasing an additional 176,496 shares during the period. Duality Advisers LP increased its holdings in Qiagen by 183.4% during the 4th quarter. Duality Advisers LP now owns 56,035 shares of the company’s stock worth $2,434,000 after purchasing an additional 36,261 shares in the last quarter. Finally, Signaturefd LLC raised its stake in shares of Qiagen by 54.4% in the 4th quarter. Signaturefd LLC now owns 7,236 shares of the company’s stock valued at $314,000 after purchasing an additional 2,550 shares during the period. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Stock Performance

Shares of QGEN stock opened at $42.95 on Wednesday. The company has a fifty day moving average price of $42.50 and a two-hundred day moving average price of $42.83. Qiagen has a one year low of $34.74 and a one year high of $47.70. The stock has a market cap of $9.80 billion, a P/E ratio of 28.80, a P/E/G ratio of 3.64 and a beta of 0.42. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.84 and a quick ratio of 1.45.

Qiagen (NYSE:QGEN) last issued its earnings results on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.02. The business had revenue of $459.00 million during the quarter, compared to the consensus estimate of $453.91 million. Qiagen had a net margin of 17.38% and a return on equity of 12.59%. Qiagen’s revenue was down 5.4% on a year-over-year basis. During the same period last year, the business posted $0.53 EPS. As a group, equities analysts predict that Qiagen will post 2.09 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Morgan Stanley upgraded Qiagen from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $49.48 to $51.00 in a report on Friday, February 16th. Citigroup reduced their price target on Qiagen from $61.86 to $60.00 and set a “buy” rating for the company in a research report on Thursday, February 8th. Stifel Nicolaus lowered their price objective on shares of Qiagen from $55.00 to $45.00 and set a “hold” rating on the stock in a report on Wednesday, May 1st. Finally, JPMorgan Chase & Co. increased their target price on shares of Qiagen from $50.00 to $52.00 and gave the stock an “overweight” rating in a report on Thursday, February 8th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.95.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.